| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2022-04-07 | Kynos Therapeutics (UK) | £6.5 million | Epidarex Capital (US) Ip Group (UK) Scottish Enterprise (UK) | Inflammatory diseases - Oncology - Metabolic diseases | Financing round | |
| 2022-03-30 | Vectivbio (Switzerland) | up to a $75 million | loan | Kreos Capital (UK) | Inflammatory diseases - Gastrointestinal diseases - Transplantation | Loan |
| 2021-12-27 | Tetraneuron (Spain) | 1million € | loan | Valencian Institute of Finance (Spain) FEDER (EU) | Neurodegenerative diseases | Loan |
| 2021-09-09 | Lexeo Therapeutics (USA-NY) | $100 Million | series B financing round | D1 Capital Partners (USA-NY) Eventide Asset Management (USA-MA) CAM Capital (USA-NY) Verition Fund Management (USA-NY) Laurion Capital Management (USA-NY) Gray’s Creek Capital Partners (USA-CT) Longitude Capital (USA-CA) Omega Funds (USA-MA) Lundbeckfonden Ventures (DK) PBM Capital (USA-VA) Janus Henderson Investors (UK) Invus (USA-NY) Woodline Partners LP (USA-CA Alexandria Venture Investments (USA-CA) | Rare diseases - Genetic diseases -Neurodegenerative diseases - Cardiovascular diseases | Series B financing round |
| 2021-06-09 | Tetraneuron (Spain) | more than €2.5 million | financing round | undisclosed private and specialised investors | Neurodegenerative diseases | Financing round |
| 2021-05-26 | Ysios Capital (Spain) | €216 million ($260 million) | Financing round | European Investment Fund (EIF) European Guarantee Fund (EGF) Health Compartment of the Sustainable Development Umbrella Fund (SDUF) | Financing round | |
| 2021-05-13 | Splisense (IL) | $28.5 million | series B financing round | Orbimed (IL) Israel Biotech Fund (IL) Biotel Limited (USA) Integra Holdings (IL) the Cystic Fibrosis Foundation (USA) | Rare diseases - Genetic diseases - Pulmonary diseases | Series B financing round |
| 2021-05-13 | Flare Therapeutics (USA - MA) | $82 million | series A financing round | Third Rock Ventures (USA - MA) Boxer Capital (USA-CA) Nextech Invest (CH) Casdin Capital (USA-NY) Invus Financial Advisors (USA-NY) Eventide Asset Management (USA-MA) | Neurological diseases - Inflammatory diseases - Immunological diseases - Rare diseases - Genetic diseases | Series A financing round |
| 2021-05-13 | Flare Therapeutics (USA-MA) | $82 million | series A financing round | Third Rock Ventures (USA-MA) Boxer Capital (USA-CA) Nextech Invest (CH) Casdin Capital (USA-CA) Invus Financial Advisors (USA-NY) Eventide Asset Management (USA-MA) | Cancer-Oncology | Series A financing round |
| 2021-04-13 | Vectivbio (Switzerland) | $146.6 million | IPO | Inflammatory diseases - Gastrointestinal diseases - Transplantation | IPO | |
| 2021-03-01 | SalioGen Therapeutics (USA - MA) | $20 Million | series A financing round | PBM Capital (USA - VA) and other undisclosed investors | Cardiovascular diseases - Ophthalmological diseases | Series A financing round |
| 2021-02-11 | Ensoma (USA - MA) | $70 million | series A financing round | 5AM Ventures (USA – MA) F-Prime Capital (USA – MA) Takeda Ventures (USA – MA) Viking Global Investors (USA – CA) Cormorant Asset Management (USA – MA) RIT Capital Partners (UK) Symbiosis II (USA – MA) Alexandria Venture Investments (USA – CA) | Cancer - Oncology - Autoimmune diseases - Infectious diseases | Series A financing round |
| 2021-01-07 | Lexeo Therapeutics | $85 Million | series A financing round | Longitude Capital (USA-CA) Omega Funds (USA-MA) Lundbeckfonden Ventures (DK) PBM Capital (USA-VA) Janus Henderson Investors (UK) Invus (USA-NY) Woodline Partners LP (USA-CA) the Alzheimer’s Drug Discovery Foundationi (USA-NY) Alexandria Venture Investments (USA-CA) | Rare diseases - Genetic diseases -Neurodegenerative diseases - Cardiovascular diseases | Series A financing round |
| 2020-10-15 | Vectivbio (Switzerland) | $110 Million | financing round | Versant Ventures (USA) OrbiMed (USA) Novo Holdings (Denmark) BPI France (France) Tekla Healthcare Investors (USA) Inserm Transfer Initiative (France) Cowen Healthcare Investments (USA) Surveyor Capital (USA) Eventide Asset Management (USA) | Inflammatory diseases - Gastrointestinal diseases - Transplantation | Fundraising |
| 2020-06-16 | eTheRNA (Belgium) | €34 M | series B financing round | LSP (the Netherlands), PMV (Belgium), Boehringer Ingelheim Venture Fund (Germany), Fund+ (Belgium), Omega Funds (USA), Grand Decade, a BVI subsidiary owned by China Grand Pharmaceutical and Healthcare Holdings Ltd; BNP Paribas Fortis Private Equity (Belgium), Yijing Capital (China), Novalis LifeSciences LLC (USA). | Immunological diseases - Infectious diseases | Series B financing round |
| 2020-01-07 | Vectivbio (Switzerland) | $35 million | fundraising | Versant Ventures (USA) OrbiMed (USA) Novo Holdings (Denmark) BPI France (France) Tekla Healthcare Investors (USA) Inserm Transfer Initiative (France) Cowen Healthcare Investments (USA) | Inflammatory diseases - Gastrointestinal diseases - Transplantation | Fundraising |
| 2019-07-24 | 20Med Therapeutics (NL) | undisclosed | grant | European Eurostars Programme (EU) | Rheumatic diseases - Inflammatory diseases | Grant |
| 2019-04-08 | Sangamo Therapeutics (USA-CA) | $136.3 million | public offering | Private placement | ||
| 2018-10-18 | Oxford Nanopore Technologies (UK) | £50 million ( $66 million ) | private placement | Amgen (USA - CA) | Technology - Services | Private placement |
| 2018-10-18 | Krystal Biotech (USA - PA) | $60.0 million | private placement | Rare diseases - Genetic diseases | Private placement |
